AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01119378 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual isotope technique
Description: Dual isotope technique using stable isotopes
Study NCT03430102 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Indicor
Description: Calculation of LVEDP via analysis of PPG waveform with Valsalva
Study NCT00801177 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-11F8
Description: Cohort 1~100 mg I.V.
Study NCT00258674 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medicare Claims Feedback
Description: Physician practices received periodic feedback on their performance on selected diabetes quality of care measures as reflected by the Medicare claims data for their patients.
Study NCT00258674 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Record Review
Description: Physician practices received period feedback on their performance on selected diabetes quality of care measures, as reflected by data collected from their patients' medical records. These data were compiled by trained nurse abstractors using a standardized data collection tool developed for this study.
Study NCT00258674 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes Resource Nurse
Description: Diabetes Resource Nurses (DRNs) were registered nurses with 3-5 years of experience as certified diabetes educations who performed initial patient assessments, developed plans of care, administered screening tools, and monitored clinical outcomes. Physicians at the practices randomised to this intervention had could access the DRN's services for their diabetes patients, but neither physicians nor patients had to take advantage of this resource.
Study NCT03886051 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Connective Tissue Graft before Orthodontic treatment
Description: Scaling and root planing will be performed and after resolution of periodontal inflammation, root coverage will be done using sub - epithelial connective tissue graft. Orthodontic treatment will be 3 months following the grafting procedure.
Study NCT03886051 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Orthodontic treatment only
Description: Scaling and root planing will be performed and after resolution of periodontal inflammation, orthodontic treatment will be initiated.
Study NCT01885611 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multi-Drug Therapy (Novartis Ⓡ)
Description: The MDT is provided by the World Health Organization (WHO) and NovartisⓇ. The MB pack consists of Rifampicin (300mg/tab x 2 tablets), Clofazimine (100mg/tab x 3 tabs and 50mg/tab x 28 tabs), Dapsone (100mg/tab x 29 tabs) and the PB pack consists of Rifampicin (300mg/tab x 2 tablets) and Dapsone (100mg/tab x 29 tabs).
Study NCT01885611 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-Drug Therapy (Novartis Ⓡ)
Description: The MDT is provided by the World Health Organization (WHO) and NovartisⓇ. The MB pack consists of Rifampicin (300mg/tab x 2 tablets), Clofazimine (100mg/tab x 3 tabs and 50mg/tab x 28 tabs), Dapsone (100mg/tab x 29 tabs) and the PB pack consists of Rifampicin (300mg/tab x 2 tablets) and Dapsone (100mg/tab x 29 tabs).
Study NCT01885611 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Virgin Coconut Oil
Description: cold-processed VCO
Study NCT03655808 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bronchial basal cells (BBCs)
Description: Airway epithelial cells were collected in patients of the cell treatment group by a disposable 2-mm brush in order to obtain BBCs. The obtained tissue were washed and enzymatically digested to form a single-cell suspension, which was then cultured under R-Clone system, a patented technique of Regend Therapeutics, Ltd.. For patients in the cell treatment group, on the basis of B-ACT therapy, they were also received autologous BBCs transplantation. Cell suspension was diluted with normal saline. Fibrotic bronchoscopy was guided into the lobular or segmental airways and cells were instilled into lobes.
Study NCT03655808 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscopic airway clearance treatment （B-ACT）
Description: The bronchoscopy was performed by board-certified respiratory physicians of Ruijin Hospital using a flexible fiber-optic bronchoscope. B-ACT therapy was performed on all patients in both groups according to the protocol. In brief, continuous suction was performed with the sputum aspirator from the trachea to the subsegmental during the entering of bronchoscope to remove the visible secretions from entire respiratory tract, and then operators used normal saline to collect lavage fluid (the volume various depending on the operator's judgement).
Study NCT03655808 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Bronchoscopic airway clearance treatment （B-ACT）
Description: The bronchoscopy was performed by board-certified respiratory physicians of Ruijin Hospital using a flexible fiber-optic bronchoscope. B-ACT therapy was performed on all patients in both groups according to the protocol. In brief, continuous suction was performed with the sputum aspirator from the trachea to the subsegmental during the entering of bronchoscope to remove the visible secretions from entire respiratory tract, and then operators used normal saline to collect lavage fluid (the volume various depending on the operator's judgement).
Study NCT02290873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: For induction and maintenance of sedation
Study NCT02290873 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: For induction of maintenance and sedation
Study NCT02290873 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive control arm
Study NCT01178450 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subtotal parathyroidectomy
Description: The procedure of choice is subtotal parathyroidectomy if the intraoperative biopsy confirms multiglandular disease and at least 3 glands are removed leaving a remanent of one normal gland
Study NCT01178450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Description: Cinacalcet is initiated at a dose of 30 mg per day PO, adjusting the dose monthly (up to 90 mg per day PO) to achieve normocalcemia
Study NCT02109900 — intervention group
Intervention type: OTHER
Intervention: Serum Progesterone Levels
Study NCT04460976 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation for Adults With Autism and Their Significant Others/Family members (Prisma)
Description: Psychoeducation in groups
Study NCT04460976 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as usual/standard care
Description: Standard care at disability/habilitation services.
Study NCT01109914 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dukoral
Description: Two oral doses of Dukoral® (SBL Vaccines) will be administered (day 0 and day 14). Each dosage contains 3 ml of suspension in a vial and 5.6 g of effervescent granules in a sachet. Each dosage (3 ml) contains: A total of 100000 million bacteria of the following strains:~* Vibrio cholerae O1 Inaba, classical biotype (heat inactivated) 25x1000 million bacteria\*~* Vibrio cholerae O1 Inaba, El Tor biotype (formalin inactivated) 25x1000 million bacteria\*~* Vibrio cholerae O1 Ogawa, classical biotype (heat inactivated) 25x1000 million bacteria\*~* Vibrio cholerae O1 Ogawa, classical biotype (formalin inactivated) 25x1000 million bacteria\*~* Recombinant cholera toxin B subunit (rCTB) 1 mg (produced in V. cholerae O1 Inaba, classical biotype strain 213)
Study NCT02287623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal bupivacaine
Description: patients will receive a tap with liposomal bupivacaine
Study NCT02287623 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Description: patients will receive a tap with bupivacaine
Study NCT04739085 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Defocus curves - Monocular distance visual acuity with trial lenses added to the best correction for distance
Description: The monocular distance visual acuity of each participant' eye is evaluated using trial lenses of -3.00 sph, -2.50 sph, -1.75 sph, and -1.25 sph (added to the best correction for distance), which correspond to distances 30 cm, 40 cm, 60 cm and 80 cm, respectively.
Study NCT04739085 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: wDDART - Monocular near visual acuity using the best correction for distance
Description: The same participants undergo visual acuity test via the web-based digital near vision reading test wDDART at 30 cm, 40 cm, 60 cm and 80 cm, having their best correction for distance.
Study NCT03982004 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epicutaneous cryoimmunotherapy
Description: Epicutaneous cryoimmunotherapy (EC) treatment includes liquid nitrogen cryotherapy applied for 10 seconds x 2 freeze-thaw cycles. Four treatment areas will be chosen at each treatment.
Study NCT03982004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical imiquimod
Description: Patients will apply the cream directly over the treatment areas and can use up to one packet per day (covers approximately 5 cm x 5 cm).
Study NCT03982004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg will be administered as a 30 minute IV infusion
Study NCT03982004 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dermatologic Quality of Life Index
Description: * 10 questions about how much skin problems has affected the participant's life over the past week~* The scoring of each question is as follows: very much = 3, a lot = 2, a little = 1, not at all = 0, not relevant = 0, and question #7 'prevented work or studying' = 3~* The DLQI is calculated by summing the score of each question resulting in a max of 30 and min of 0. The higher the score, the more quality of life is impaired.
Study NCT03982004 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Assessment of Cancer Therapy
Description: * 5 subscales (physical well-being, social/family well-being, emotional well-being, functional well-being, and additional concerns)~* Answers ranging from 0=Not at all to 4 = very much~* Each item is rated on a 5-point Likert scale.~* The higher the score on the social/family well-being and functional well-being indicate higher quality of life~* The lower the score on physical well-being, emotional well-being, and additional concerns indicate higher quality of life
Study NCT03982004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-lesional GM-CSF
Description: 250 mcg every 2 weeks x 3 doses then every 3 weeks for 3 doses
Study NCT03982004 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cry-AC
Description: -Device used to give the cryoimmunotherapy
Study NCT03982004 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cutaneous tumor biopsy
Description: -Baseline, week 3 (prior to 1st dose of pembrolizumab), week 9, and at week 18. An optional biopsy can be obtained at the time of disease progression.
Study NCT03982004 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood draw for research
Description: -Baseline, week 3 (prior to 1st dose of pembrolizumab), week 9, and at week 18. An optional biopsy can be obtained at the time of disease progression.
Study NCT03518788 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pleur-X
Description: Permanent drainage
Study NCT03518788 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pleurodesis
Description: Pleurodesis with talc in permanent VATS
Study NCT03518879 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ASTHMA-Educator mobile application
Description: The on-site delivered ASTHMA-Educator mobile application.
Study NCT00259883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paroxetine
Description: 1 or 2 tablets once a day
Study NCT01230541 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily, oral tablet
Study NCT01230541 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Udenafil
Description: Daily tablet
Study NCT04341441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine - Daily Dosing
Description: The daily hydroxychloroquine treatment arm will receive a 200 mg oral dose daily following day 1 dose of 400 mg orally once. This dose represents approximately half the standard weight-based dosing recommended for management of autoimmune diseases and therefore less likely to produce side effects than standard of care.~All treatment groups will receive placebo pills to have the patients take 2 pills a day.
Study NCT04341441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine - Weekly Dosing
Description: The once weekly randomized treatment arm will receive the proposed dose of hydroxychloroquine for prophylaxis of malaria is 6.5 mg/kg per dose (maximum of 400 mg per dose) administered orally weekly on the same day of each week. This is based on the recommended dose for prophylaxis of malaria~All treatment groups will receive placebo pills to have the patients take 2 pills a day.
Study NCT04341441 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo oral tablet
Description: Participants randomized to this arm will be provided with daily dosing of oral placebo to have the patients take 2 pills a day..~Participants will receive a monitoring phone call at 4 weeks post study entry to monitor for COVID-19 symptoms and medication side effects. At week 8, participants will provide additional samples of whole blood.~Additional studies will include serology, inflammatory and other disease associated markers. Clinical data and location of main work area will be collected.
Study NCT04341441 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Monitoring Visit - Baseline
Description: Face-to-face monitoring visit to obtain monitoring questionnaires to assess for COVID-19 symptoms/diagnosis, adherence and medication side effects, and collect study blood samples. Three (3) blood specimens will be collected from each Participant using the sterile procedure as routine standard of care. A total of five (5) 10 mL tubes of whole blood will be collected at each timepoint.
Study NCT04341441 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Monitoring Visit - Week 4
Description: Face-to-face monitoring visit to obtain monitoring questionnaires to assess for COVID-19 symptoms/diagnosis, adherence and medication side effects, and collect study blood samples. Three (3) blood specimens will be collected from each Participant using the sterile procedure as routine standard of care. A total of five (5) 10 mL tubes of whole blood will be collected at each timepoint.
Study NCT04341441 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Monitoring Visit - Week 8
Description: Face-to-face monitoring visit to obtain monitoring questionnaires to assess for COVID-19 symptoms/diagnosis, adherence and medication side effects, and collect study blood samples. Three (3) blood specimens will be collected from each Participant using the sterile procedure as routine standard of care. A total of five (5) 10 mL tubes of whole blood will be collected at each timepoint.
Study NCT04341441 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Weekly Assessment
Description: Participants will be asked to contact the study team if COVID-19 infection is established at any time during the study. For study weeks 1,2,3,5,6 \&7, Participants will receive a monitoring questionnaire to assess for COVID-19 symptoms/diagnosis, adherence and medication side effects. These monitoring visits will be done by telephone and/or electronic encounters (virtual visits, email), whichever method the patient prefers to encourage adherence to the monitoring.
Study NCT05219942 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glargine
Description: regular low dose insulin infusion 0.1 IU/Kg/hour and subcutaneous Glargine insulin (made by Sanofi®) within the first 2 hours of ICU admission. The dose of insulin glargine will be adjusted according to the calculated (eGFR > 90 dose = 0.27 IU/kg/day, eGFR 60-89 dose = 0.25 IU/kg/day, eGFR \<60 dose = 0.19 IU/kg/day.
Study NCT05219942 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: regular low dose insulin infusion 0.1 IU/Kg/hour and subcutaneous saline instead of insulin glargine will be given in the control group.
Study NCT03260088 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Immunoglobulin G4
Description: IgG4 will be purified from pleural fluids by diethylaminoethyl (DEAE)-cellulose ion exchange nephlometry
Study NCT03471975 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: direct laryngoscope
Description: the trainee use McGrath video laryngoscope as direct laryngoscope the trainee is not allowed to watch the screen.
Study NCT03471975 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: video laryngoscope
Description: the trainee use McGrath video laryngoscope both trainee and trainer can watch the screen.
Study NCT00554502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: supportive therapy with: ACE-inhibitor / ARB / Statin
Description: * Antihypertensive therapy with a target blood pressure below 125/75 mmHg (following current clinical guidelines).~* ACE-inhibitors (ARB when an ACE-inhibitor is not tolerated)~* Other antihypertensive medications depending on the clinical decision and following current guidelines.~* Statin therapy~* Dietary counseling for a low-sodium diet and, if GFR is below 60 ml/min, for a protein intake of 0.8 g/kg/day.
Study NCT00554502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: supportive and immunosuppressive therapy
Description: * supportive therapy as outlined above~* depending on GFR:~  * methylprednisolone and prednisolone~ * cyclophosphamide and prednisolone; after 3 months azathioprine with prednisolone~* Concomitant medication with the immunosuppressive treatment following current clinical practice
Study NCT03134170 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pharmacist review of therapy
Description: Patients who are randomized to the pharmacist group will have their treatment reviewed by a pharmacist
Study NCT01747642 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oncoxin
Description: Syp Oncoxin 25 ml bd and Cap. Oncoxin bd for 180 days
Study NCT01747642 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Suranix
Description: Tab Suranix 200 mg 2 tab bd and Syp Oncoxin 25 ml bd and Cap. Oncoxin bd for 180 days
Study NCT04597736 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological collection with nasopharyngeal samples, saliva, blood, stool and urine
Description: Subjects with a COVID-19 infection and their contact cases (identification according to health insurance criteria, see Améli.fr) will be offered a clinical evaluation and the takin of biological samples, whether they are hospitalized or via the outpatient screening channel.~For the main objective: during the Day0 visit, the subjects who agreed to participate in the study will have a clinical evaluation according to a standardized questionnaire and a nasopharyngeal swab, saliva, blood, stool and urine.~For secondary objectives : longitudinal follow-up will be carried out for 21 days, for index cases and contact cases, whether they have a positive or negative RT-PCR test on D0. A final consultation will be carried out at M3. Nasopharyngeal samples, saliva, blood, stool and urine will be taken on D10 and D21. A blood test will be taken at M3 to carry out a COVID-19 serology.
Study NCT04425187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gefitinib
Description: gefitinib 250mg (1 tablet), once a day，PO
Study NCT04425187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab Combined With Gefitinib
Description: Bevacizumab Combined With Gefitinib
Study NCT05218512 — intervention group
Intervention type: OTHER
Intervention: WB-EMS
Description: The group has been submitted to 2 experimental conditions:~1. At rest with superimposed WB-EMS.~2. During uphill walking exercise with superimposed WB-EMS.
Study NCT00000299 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Study NCT00000299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Study NCT00004138 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Study NCT00004138 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radionuclide imaging
Study NCT00004138 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Study NCT02734836 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balloon Angioplasty
Study NCT02734836 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography
Study NCT02084303 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ferumoxytol injection after focal epileptic seizure followed by iron-sensitive MRI
Study NCT00645593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine,
Description: Gemcitabine will be administered intravenously at a dose of 1000 mg/m2 on Days 1, 8 and 15 of cycle. One treatment cycle is 28 days.
Study NCT00645593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine,
Description: Gemcitabine will be administered intravenously at a dose of 1000 mg/m2 on Days 1, 8 and 15 of cycle. One treatment cycle is 28 days.
Study NCT00645593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin will be administered intravenously at a dose of 70 mg/m2 per institutional standards on Day 1 of each cycle.
Study NCT00645593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be administered intravenously at a dose of 70 mg/m2 per institutional standards on Day 1 of each cycle.